Literature DB >> 15698608

Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers.

Gabor E Linthorst1, Anouk C Vedder, Johannes M F G Aerts, Carla E M Hollak.   

Abstract

INTRODUCTION: Recently, a method to analyse dried whole blood spots to diagnose Fabry disease (deficiency of the lysosomal enzyme alpha-Gal A) was described. However given its X-linked inheritance female Fabry patients can exhibit normal alpha-Gal A activities. This could lead to underestimation in screening females for Fabry disease using this method.
METHODS: alpha-Gal A activity was measured in dried whole blood spots of 21 females with documented Fabry disease.
RESULTS: Only 13/21 (67%) had reduced alpha-Gal A activities, concluding that one-third of female carriers would not be identified during screening. Additional determination of alphaGlucosidase activity (alphaGlu) and the construction of an alphaGal/alphaGlu ratio did not increase sensitivity of the assay.
CONCLUSION: Assays using alpha-Gal activity for determination of Fabry disease in females have a high false-negative value. Screening for alpha-Gal A deficiency by means of whole blood spots should not be performed in a females.

Entities:  

Mesh:

Year:  2005        PMID: 15698608     DOI: 10.1016/j.cccn.2004.10.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  25 in total

1.  Female with Fabry Disease Unknowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Genetic Testing.

Authors:  Lindsay S Paull; Michael J Lipinski; William G Wilson; Shawn E Lipinski
Journal:  JIMD Rep       Date:  2011-12-06

Review 2.  Monogenic causes of stroke: now and the future.

Authors:  Rhea Y Y Tan; Hugh S Markus
Journal:  J Neurol       Date:  2015-06-03       Impact factor: 4.849

3.  Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells.

Authors:  Christine R Kaneski; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  J Lipid Res       Date:  2010-06-06       Impact factor: 5.922

4.  Proteinuria in a male adolescent with hearing loss: Answers.

Authors:  Gülşah Kaya Aksoy; Elif Çomak; Bahar Akkaya; Mustafa Koyun; Sema Akman
Journal:  Pediatr Nephrol       Date:  2017-11-02       Impact factor: 3.714

5.  Newborn screening for lysosomal storage diseases: an ethical and policy analysis.

Authors:  Lainie Friedman Ross
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

6.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

7.  Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?

Authors:  Juan Politei; Valeria Alberton; Oscar Amoreo; Norberto Antongiovanni; Maria Nieves Arán; Marcelo Barán; Gustavo Cabrera; Silvia Di Pietrantonio; Consuelo Durand; Alejandro Fainboim; Joaquin Frabasil; Fernando Gomez Pizarro; Roberto Iotti; Miguel Liern; Fernando Perretta; Diego Ripeau; Fernanda Toniolo; Hernan Trimarchi; Dana Velasques Rivas; Eric Wallace; Andrea Beatriz Schenone
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

8.  Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry.

Authors:  Yung-Hsiu Lu; Po-Hsun Huang; Li-Yun Wang; Ting-Rong Hsu; Hsing-Yuan Li; Pi-Chang Lee; Yu-Ping Hsieh; Sheng-Che Hung; Yu-Chen Wang; Sheng-Kai Chang; Ya-Ting Lee; Ping-Hsun Ho; Hui-Chen Ho; Dau-Ming Niu
Journal:  J Hum Genet       Date:  2017-11-15       Impact factor: 3.172

9.  Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.

Authors:  Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Toya Ohashi; Masahisa Kobayashi; Yoshikatsu Eto; Akemi Tanaka; Hideo Odaka; Misao Owada
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

Review 10.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.